Shots:

• The sBLA approval is based on P-III immunogenicity and safety study assessing Fluzone High-Dose Quadrivalent vs two trivalent formulations of Fluzone High-Dose in 32-000 adults aged≥ 65yrs. over two influenza seasons in the US and Canada
• The P-III results demonstrated that Fluzone High-Dose Quadrivalent prevent 24% more cases of influenza caused by any circulating influenza strain and 51% more cases of influenza caused by strains like those contained in the vaccine
• The Fluzone High-Dose Quadrivalent contains an additional influenza B strain and has filed sBLA in regulatory bodies outside the US with its anticipated EMA’s approval in H2’20. The vaccine will be available in the US for immunization during the 2020-2021 influenza season

Click here to­ read full press release/ article | Ref: Sanofi | Image: Glassdoor